HEALER
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- NCT05838066 ↗
- Recruiting
- Shanghai JMT-Bio Inc.
- Focused
We haven't built an HCP commentary report on HEALER (recombinant humanized bispecific antibody against HER2，KN026, HB1801 and 3 more in First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HEALER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- Interventions
- Recombinant Humanized Bispecific antibody against HER2，KN026; HB1801; Pertuzumab; Trastuzumab; Docetaxel
- Arms
- KN026+HB1801 · Experimental
- Trastuzumab + Pertuzumab + Docetaxel · Active comparator
- Enrollment
- 880 (estimated)
- Primary outcomes
- Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).
- Sponsor
- Shanghai JMT-Bio Inc.
- Start
- Jul 23, 2023
- Primary completion
- Jul 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05838066 · updated May 30, 2025
Publications
linked from the registry- Wang J, Li H, Xu F, Wu T, Tong Z, Cui J, Wang X, Song Z, Sun T, Li H, Xie W, Sun J, Zhang X, Teng Y, Li X, Zhu J, Luo T, Zhao B, Ning F, Xie C, Gan L, Yin G, Li Y, Yuan C, You W, Wu Z, Liu Q, Kong X, Chang J, Zhao J, Zhai Z, Ouyang Q, Han X, Li F, Nie J, Han G, Xia C, Huang W, Xiang S, Zou K, Wang Y, Xu B. Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2610345. Online ahead of print. PubMed 42929681